IGDRP – Mission, Scope, How it works

IGDRP–EDQM Workshop
Strasbourg, France
13 May 2016

Dr. Craig Simon
Associate Director,
Bureau of Pharmaceutical Sciences
Therapeutic Products Directorate
Health Canada

Outline

- Concept
- History
- Mission
- Objectives
- Participants
- Organisation
- Governance
- Operating Principles
- Activities
Access to affordable, quality generic drugs increasingly important in containing health care costs

Effective coordination for multiple initiatives on a number of fronts

Form an international collaborative effort in the area of generic drug review

Followed a step-wise approach:
- started by assessing feasibility and interest in such a concept through discussions with regulatory authorities and multinational generic companies

Timing was right:
- Common requirements in some areas and format provided by ICH (CTD) guidelines
- Increasing prevalence of multi-national generic companies, including generic arms of brand name companies
- Success of existing models:
  - EU’s De-Centralised Procedure (DCP) and Centralised Procedure (CP)
  - WHO’s Pre-Qualification Programme
  - OECD (new pesticides)
- Restricted set of scientific disciplines (as compared with new active substances)
History

2011  Exploratory meeting: Ottawa, November

2012  Launch of 3 year Pilot: Washington, April  Nanchang, December

2013  Canberra, May  Geneva, October

2014  Yilan, May  Singapore, November

2015  Transition to Programme: Pretoria, May  Seoul, November

2016  Strasbourg, May

Mission and Goal

Mission

◦ Promote collaboration & convergence in generic drug regulation to strengthen the ability of health authorities to meet their respective mandates

Goal

◦ Facilitate efficient use of resources and timely authorization and availability of efficacious, safe and quality generic products
Create conditions which enable greater inter-agency collaboration.
Foster peer discussion to bring a broader set of perspectives to bear on scientific and regulatory issues.
Promote greater alignment of regulatory approaches and technical requirements based on international standards and best practices.
Enhance and better coordinate the international regulatory oversight of generic drug products.
Promote the adoption of modern science- and risk-based approaches to the development and regulation of generic drug products.
Promote increased efficiency, consistency and predictability in regulatory assessments and decisions.

Enhance communication, information-sharing, and scientific exchange leading to greater work-sharing and potential mutual reliance on regulatory assessments.
Promote transparency and clarity of regulatory and procedural requirements.
Enhance the development of human resources and competencies.
Reduce regulatory burden without compromising the safety, efficacy, or quality of generic drug products.

International collaborative effort in the area of generic products
Active Participants

- Australia
- Brazil
- Canada
- Chinese Taipei
- CMDh (EU)
- EDQM
- Japan
- Korea
- Mexico
- Singapore
- South Africa
- Switzerland
- USA
- WHO

Organisation

IGDRP

Steering Committee

Secretariat

WG  WG  WG
 Governance

- IGDRP consists of a Steering Committee and Working Groups
- Role of the Steering Committee:
  ◦ makes decisions on behalf of the IGDRP;
  ◦ provides strategic direction;
  ◦ identifies and prioritises challenges to be addressed and collaborative activities;
  ◦ determines the implementation process and monitors the work plan(s); and
  ◦ authorises resources in support of advancing the IGDRP’s goals and objectives.
- The Steering Committee is made up of one representative from each participating member and one observer each from the World Health Organization (WHO) and the European Directorate for the Quality of Medicines (EDQM)

 Operating Principles

- Voluntary
- Consensus driven in terms of governance and administrative issues
- Participating regulators may “opt-out” from particular work plan activities
  ◦ Provides necessary operational flexibility given diversity in systems and capacities
- Activities will complement and not duplicate work undertaken in other international activities
Overarching Activities

- Two face-to-face meetings/year, chair of Steering Committee and host rotate with each meeting (chair becomes the co-chair of subsequent meeting)
- Work continued via teleconference between meetings

- Regulatory Gap Analysis (lead: ANVISA, Brazil)
- Comparison of review process and features – legislation, key regulatory guidelines, phases of the application process, timelines, user fees (lead: HSA, Singapore)
- IT platform/central repository (lead: Swissmedic, Switzerland)
- Information and Work Sharing models:
  - Decentralised Procedure (DCP) pilot (launched July 2014)
  - Centralised Procedure (CP) pilot (launched Jan. 2015)
  - Sharing of EU assessment reports in “real time”
Activities – Working Groups

Quality Working Group
- Establish frameworks and mechanisms for information sharing and work sharing
- Focus on ASMF/DMF

Bioequivalence Working Group
- Survey and collate and publish information from each jurisdiction
- Develop tools (e.g., assessment templates, guidance for assessors) to aid in assessment
- Focus on biowaivers

The Future

Drivers to Continue:
- New and emerging science, medicines and technologies;
- Globalisation of issues and production chains;
- Emerging public health threats and needs;
- Sustainability and appropriateness of regulatory systems and oversight;
- Need to support risk-based and science-based review functions;
- Interest and the need for international alignment and sharing of best practices;
- Governmental initiatives for regulatory convergence and cooperation;
- Need for modernised information sharing systems;
- Public demand for greater openness and transparency and availability of information to make informed decisions.
The Future (cont’d)

- Roadmap under development that will:
  - make available a strategic vision to articulate and guide the collective efforts of IGDRP in terms of where we are going and how we are going to get there;
  - provides overarching concepts for the strategic priorities, describes inter-dependencies, as well the key objectives that will facilitate an assessment of the success of meeting our common goals.

The Future (cont’d)

- Ongoing projects of Quality WG and Bioequivalence WG
- Ongoing Worksharing projects – DCP and CP Worksharing Pilot

- Next IGDRP Meeting: 17–20 October 2016, Mexico City, Mexico

- Contact: IGDRPSecretariat@tga.gov.au
- Website: www.igdrg.com
Thinking globally, acting locally

Thank you